SAM
ABBV icon

S.A. Mason’s AbbVie ABBV Stock Holding History

S.A. Mason’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.23M Buy
12,345
+6
+0% +$1.54K 0.95% 22
2026
Q2 		$3.1M Buy
12,339
+106
+0.9% +$22.8K 0.95% 22
2026
Q1 		$2.66M Buy
12,233
+191
+2% +$42.4K 1% 21
2025
Q4 		$2.75M Sell
12,042
-146
-1% -$33.3K 1.09% 19
2025
Q3 		$2.82M Sell
12,188
-99
-0.8% -$20.2K 1.25% 15
2025
Q2 		$2.28M Sell
12,287
-2
-0% -$372 1.1% 16
2025
Q1 		$2.57M Sell
12,289
-456
-4% -$88.6K 1.36% 13
2024
Q4 		$2.26M Buy
12,745
+104
+0.8% +$19.1K 1.19% 14
2024
Q3 		$2.5M Buy
12,641
+18
+0.1% +$3.36K 1.32% 13
2024
Q2 		$2.17M Buy
12,623
+336
+3% +$55.7K 1.23% 14
2024
Q1 		$2.24M Buy
12,287
+20
+0.2% +$3.45K 1.35% 13
2023
Q4 		$1.9M Sell
12,267
-83
-0.7% -$12.1K 1.27% 13
2023
Q3 		$1.84M Sell
12,350
-548
-4% -$80.4K 1.33% 14
2023
Q2 		$2.06M Hold
12,898
– – 1.49% 12
2023
Q1 		$2.06M Buy
12,898
+214
+2% +$32.7K 1.49% 12
2022
Q4 		$2.05M Sell
12,684
-36
-0.3% -$5.52K 1.54% 11
2022
Q3 		$1.71M Sell
12,720
-171
-1% -$24.5K 1.35% 11
2022
Q2 		$1.97M Buy
12,891
+45
+0.4% +$6.88K 1.44% 11
2022
Q1 		$2.08M Buy
12,846
+556
+5% +$80.8K 1.3% 12
2021
Q4 		$1.66M Buy
12,290
+16
+0.1% +$1.89K 1% 19
2021
Q3 		$1.32M Buy
12,274
+738
+6% +$84.3K 0.87% 25
2021
Q2 		$1.3M Sell
11,536
-2
-0% -$225 0.89% 27
2021
Q1 		$1.25M Sell
11,538
-16
-0.1% -$1.71K 0.93% 24
2020
Q4 		$1.24M Sell
11,554
-92
-0.8% -$8.84K 1.03% 20
2020
Q3 		$1.02M Buy
11,646
+8
+0.1% +$753 0.97% 29
2020
Q2 		$1.14M Buy
11,638
+8
+0.1% +$704 1.2% 15
2020
Q1 		$886K Sell
11,630
-66
-0.6% -$5.62K 1.08% 20
2019
Q4 		$1.04M Buy
+11,696
New +$971K 0.99% 24

Other funds holding ABBV

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Hamlin Capital Management
Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Ferguson Wellman Capital Management
Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

S.A. Mason's ABBV Position: Q3 2026 in Review

S.A. Mason increased its AbbVie (ABBV) stake by 0.05% in Q3 2026, buying an estimated $1.54K and bringing the position to 12,345 shares worth $3.23M. The position accounts for 0.95% of the portfolio, ranked #22.

S.A. Mason first reported a position in ABBV in Q4 2019 and has held it in 28 quarters since. 921 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • S.A. Mason held 12,345 shares of AbbVie worth $3.23M as of Q3 2026.
  • S.A. Mason bought 6 AbbVie shares in Q3 2026, an estimated $1.54K.
  • AbbVie made up 0.95% of S.A. Mason's portfolio in Q3 2026, its #22 holding.
  • S.A. Mason first reported a position in AbbVie in Q4 2019 and has held it in 28 quarters since.
  • 921 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on S.A. Mason's 13F filing for Q3 2026, filed 13 Oct 2026.